Literature DB >> 999347

Long-term patency of vein grafts preserved in liquid nitrogen in dimethyl sulfoxide.

T R Weber, S M Lindenauer, T L Dent, E Allen, C A Salles, L Weatherbee.   

Abstract

Autogenous canine jugular veins were stored in 15% dimethyl sulfoxide (DMSO) in liquid nitrogen vapor for one to 28 days and then implanted in the carotid artery as autografts. The patency rate at one year was 62.5-87.5%. The patency rate of fresh jugular vein autografts placed in the carotid artery for one year was 75%. Similar autografts stored in liquid nitrogen vapor for one to 28 days without the cryopreservative DMSO exhibited a zero to 12.5% patency rate at one year. Scanning electron microscope studies revealed preservation of theendothelium in DMSO protected veins and a damaged or sloughed endothelium in veins frozen without DMSO cryopreservation.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 999347      PMCID: PMC1345412          DOI: 10.1097/00000658-197612000-00008

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  11 in total

1.  Preservation of living cells.

Authors:  H T MERYMAN
Journal:  Fed Proc       Date:  1963 Jan-Feb

2.  Viable vein graft preservation.

Authors:  T R Weber; T L Dent; S M Lindenauer; E Allen; L Weatherbee; H H Spencer; P Gleich
Journal:  J Surg Res       Date:  1975-03       Impact factor: 2.192

3.  Cryopreservation of vein grafts.

Authors:  T L Dent; T R Weber; S M Lindenauer; N Ascher; L Weatherbee; E Allen; H H Spencer
Journal:  Surg Forum       Date:  1974

4.  Biologic fate of autogenous vein implants as arterial substitutes: clinical, angiographic and histopathologic observations in femoro-popliteal operations for atherosclerosis.

Authors:  D E Szilagyi; J P Elliott; J H Hageman; R F Smith; C A Dall'olmo
Journal:  Ann Surg       Date:  1973-09       Impact factor: 12.969

5.  Mechanism of cryoinjury in biological systems.

Authors:  G G Litvan
Journal:  Cryobiology       Date:  1972-06       Impact factor: 2.487

6.  Use of saphenous vein homografts for arterial reconstruction: a preliminary report.

Authors:  D A Tice; E Santoni
Journal:  Surgery       Date:  1970-03       Impact factor: 3.982

7.  Living homologous saphenous vein in geriatric femoropopliteal bypass grafting--report of a case.

Authors:  D R Jackson
Journal:  Vasc Surg       Date:  1971 Jan-Feb

8.  Experience with fresh venous allografts as an arterial substitute.

Authors:  J L Ochsner; P T DeCamp; G L Leonard
Journal:  Ann Surg       Date:  1971-06       Impact factor: 12.969

9.  Long-term survival following coronary artery bypass. Analysis of 4,522 consecutive patients.

Authors:  G J Reul; D A Cooley; D C Wukasch; E R Kyger; F M Sandiford; G L Hallman; J C Norman
Journal:  Arch Surg       Date:  1975-11

10.  Autogenous venous femoropopliteal bypass grafts.

Authors:  J A DeWeese; R Terry; H B Barner; C G Rob
Journal:  Surgery       Date:  1966-01       Impact factor: 3.982

View more
  5 in total

1.  In situ spectroscopic quantification of protein-ice interactions.

Authors:  Alan Twomey; Rebekah Less; Kosaku Kurata; Hiroshi Takamatsu; Alptekin Aksan
Journal:  J Phys Chem B       Date:  2013-06-20       Impact factor: 2.991

2.  Antigenicity of venous allografts.

Authors:  S C Axthelm; J M Porter; S Strickland; G M Baur
Journal:  Ann Surg       Date:  1979-03       Impact factor: 12.969

3.  Preparation of venous allografts. A comparison of techniques.

Authors:  S C Balderman; M Montes; K Schwartz; T Hart; J N Bhayana; A A Gage
Journal:  Ann Surg       Date:  1984-08       Impact factor: 12.969

4.  Cryopreserved saphenous vein allografts for below-knee lower extremity revascularization.

Authors:  R S Martin; W H Edwards; J L Mulherin; W H Edwards; J M Jenkins; S J Hoff
Journal:  Ann Surg       Date:  1994-06       Impact factor: 12.969

5.  Pharmacological studies on frozen stored canine saphenous veins and basilar arteries.

Authors:  E Müller-Schweinitzer; C Tapparelli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-01       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.